Oncopeptides Management
Management criteria checks 2/4
Oncopeptides' CEO is Sofia Heigis, appointed in Aug 2023, has a tenure of less than a year. total yearly compensation is SEK3.18M, comprised of 55.3% salary and 44.7% bonuses, including company stock and options. directly owns 0.009% of the company’s shares, worth SEK65.77K. The average tenure of the management team and the board of directors is 1.3 years and 6.6 years respectively.
Key information
Sofia Heigis
Chief executive officer
SEK 3.2m
Total compensation
| CEO salary percentage | 55.3% |
| CEO tenure | less than a year |
| CEO ownership | 0.009% |
| Management average tenure | 1.3yrs |
| Board average tenure | 6.6yrs |
Recent management updates
No updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | SEK 3m | SEK 2m | -SEK 249m |
Compensation vs Market: Sofia's total compensation ($USD294.28K) is about average for companies of similar size in the Swedish market ($USD249.58K).
Compensation vs Earnings: Insufficient data to compare Sofia's compensation with company performance.
CEO
Sofia Heigis (43 yo)
less than a year
Tenure
SEK 3,180,000
Compensation
Ms. Sofia Heigis, M.sc, was Chief Commercial Officer and Managing Director of Germany at Oncopeptides AB (publ) since 2022 until 07 August 2023 and also serves as its CEO since 07 August 2023. Ms. Heigis j...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Executive Officer | less than a year | SEK 3.18m | 0.0092% SEK 65.8k | |
| Chief Scientific Officer | 1.3yrs | SEK 4.84m | 0.40% SEK 2.8m | |
| Founder | no data | no data | no data | |
| Founder | no data | no data | no data | |
| Founder | no data | no data | no data | |
| Founder | no data | no data | no data | |
| Founder | no data | no data | no data | |
| Founder | no data | no data | no data | |
| Chief Financial Officer | less than a year | no data | no data | |
| COO & Deputy MD | 4.3yrs | no data | 0.055% SEK 393.1k | |
| Director of IR & Communications | 1.3yrs | no data | no data | |
| Head of Human Resources | 6yrs | no data | 0.000040% SEK 286.9 |
1.3yrs
Average Tenure
49yo
Average Age
Experienced Management: ONCO BTA's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Independent Chairman of the Board | 6yrs | SEK 1.63m | 0.18% SEK 1.3m | |
| Independent Director | 12.3yrs | SEK 355.00k | no data | |
| Independent Director | 7.3yrs | SEK 682.50k | 0.0054% SEK 38.6k | |
| Member of Clinical Advisory Board | no data | no data | no data | |
| Independent Director | 13.1yrs | SEK 627.50k | 0.026% SEK 188.9k | |
| Independent Director | 6yrs | SEK 755.00k | no data | |
| Member of Clinical Advisory Board | no data | no data | no data | |
| Independent Director | 5.4yrs | SEK 755.00k | no data | |
| Member of Clinical Advisory Board | no data | no data | no data | |
| Member of Clinical Advisory Board | no data | no data | no data |
6.6yrs
Average Tenure
65yo
Average Age
Experienced Board: ONCO BTA's board of directors are considered experienced (6.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/05/15 23:58 |
| End of Day Share Price | 2024/05/13 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Oncopeptides AB (publ) is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Erik Hultgård | Carnegie Investment Bank AB |
| Patrik Ling | DNB Markets |
| Robert Burns | H.C. Wainwright & Co. |